curacle큐라클
365270 · KOSDAQ · ₩365270 · 큐라클
- Market cap
- ₩176B
- Enterprise value
- ₩164B
- P/E
- —
- P/B
- 3.8×
- Dividend yield
- 0.0%
- ROE
- −16.2%
- Net margin
- −106,851.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−61.8% from the high
₩4,400Today: ₩7,890 – ₩8,490₩20,750
Returns
- 1W−12.2%
- 1M−17.1%
- 3M−0.6%
- 6M−54.8%
- YTD+11.2%
- 1Y+29.6%
- Volume today
- 57,996
- 1.0× the 20-day average
- Traded today
- ₩468M
- Listed shares
- 22,156,992
- EPS (12 months)
- −₩342
- Earnings yield −4.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- MomentumWeak-14% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
curacle stock overview
curacle (큐라클, KRX: 365270) is listed on KOSDAQ, in the Biotech & Pharma sector. Curacle is a Korean biotech venture company that develops drugs aimed at normalizing endothelial dysfunction to address the root causes of various intractable diseases. Its shares closed at ₩7,930 on Oct 27, 2026, down 3.65% on the day, giving it a market value of ₩176B.
Key facts
- Market cap
- ₩176B
- Sector
- Biotech & Pharma
- Latest price change
- −3.65%
- As of
- Oct 27, 2026
- Main business
- Curacle is a Korean biotech venture company that develops drugs aimed at normalizing endothelial dysfunction to address the root causes of various intractable diseases.
Quick answers about curacle
- What does curacle do?
- Curacle is a Korean biotech venture company that develops drugs aimed at normalizing endothelial dysfunction to address the root causes of various intractable diseases. Its pipeline includes small-molecule candidates from its SOLVADYS platform and antibody candidates developed with partner Mapics, targeting retinal, kidney, neurodegenerative, and thrombotic conditions. The company's business model is out-licensing and co-development rather than product sales, and its lead candidate Rivasterat is being developed for retinal diseases, with business development activities targeting global pharmaceutical partners in North America, Asia, and Europe.
- What is the market cap of curacle?
- The market capitalisation of curacle was ₩176B at the close on Oct 27, 2026.
- Who are the largest shareholders of curacle?
- According to the latest official filings, the largest reported holders are Kwon Young-geun (9.71%, as of Sep 12, 2025); National Pension Service (0.50%, as of Dec 31, 2021); Kim Young-myung (0.30%, as of Sep 12, 2025).
- When is the next earnings report from curacle?
- Korean companies rarely announce results dates in advance. Based on when curacle filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own curacle?
- Yes. The National Pension Service held 0.50% of curacle shares as of Dec 31, 2021.
Company profile
Curacle is a Korean biotech venture company that develops drugs aimed at normalizing endothelial dysfunction to address the root causes of various intractable diseases. Its pipeline includes small-molecule candidates from its SOLVADYS platform and antibody candidates developed with partner Mapics, targeting retinal, kidney, neurodegenerative, and thrombotic conditions. The company's business model is out-licensing and co-development rather than product sales, and its lead candidate Rivasterat is being developed for retinal diseases, with business development activities targeting global pharmaceutical partners in North America, Asia, and Europe.
Written by AI from the company's latest annual report.
- Korean name
- 큐라클
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 유재현
- Founded
- May 2016
- Listed
- Jul 2021
- Listed shares
- 22,156,992
- Fiscal year ends
- Month 12
- Website
- www.curacle.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Insider shareholding reportJun 10, 2026
- Insider shareholding reportJun 10, 2026
- Insider shareholding reportJun 10, 2026
- Insider shareholding reportJun 10, 2026
Titles in Korean until English translations are added.
Also known as: curacle / 큐라클 / 365270 / KRX:365270
Source: KRX statistical information